ERBB2 and neoplasm: Consistent with a dependency on costimulation for full T cell activation, the newly engineered αVEGFR2–αCD3ε bsAb showed a reactivity profile similar to previously reported αCD3ε bsAb with EpCAM, HER2, EGFR, or CEA tumor antigen specificities, the reactivity of which was strongly augmented by costimulatory bsAb [20].